GlassScriptPhysician profile
Hammad H Bokhari
NPI 1104832161
$8,274.52
in general payments reported to CMS, 2019-2025
49 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,711 · 2020: $1,142 · 2021: $971 · 2022: $515 · 2023: $649 · 2024: $1,060 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.21 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Merz North America, INC. | $1,119.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $872.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Allergan, INC. | $555.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $532.82 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $402.46 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $394.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $381.53 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $296.88 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $218.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $213.70 | 2019-2025 | Veozah |
| Lundbeck LLC | $159.31 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $142.53 | 2019 | |
| Sunovion Pharmaceuticals INC. | $131.08 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $131.02 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Bokhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.